Hansa Biopharma Reports Strong Q1 Performance
Strong product sales and key progress in pipeline catalysts
Hansa Biopharma AB, referred to as 'Hansa' or the 'Company' (Nasdaq Stockholm: HNSA), recently shared its interim financial results for the first quarter of 2025, demonstrating significant advancements and strong revenue performance.
Peter Nicklin, the Chairman of the Board at Hansa Biopharma, emphasized the impressive growth achieved during Q1, highlighting total revenues reaching 66.3 million SEK, with product sales of 65.7 million SEK. This indicates a remarkable 39% increase compared to the same quarter in the previous year, when the revenue stood at 47.4 million SEK. Nicklin noted that while the organ allocation market continues to be unpredictable, Hansa remains optimistic about its year-on-year revenue expansion.
In addition to strong sales, Hansa completed the enrollment for its Post Authorization Efficacy and Safety (PAES) study, further securing access and reimbursement in three new European markets. The use of IDEFIRIX (imlifidase) is on the rise in important medical centers across Europe, underscoring the drug’s increasing acceptance and utilization. Looking ahead, Hansa anticipates several critical pipeline catalysts in the latter half of 2025, particularly concerning the U.S. ConfIdeS Phase 3 trial in kidney transplantation, alongside another pivotal trial for anti-GBM.
Following the celebrated results of the 15-HMedIdeS-09 single-arm Phase 2 study in Guillain-Barre Syndrome (GBS), Hansa is eager to present this promising data at future medical congresses. Concurrently, development of the next-generation molecule HNSA-5487 for repeat dosing continues to progress, with encouraging feedback received from BfArM about its clinical development strategy targeting myasthenia gravis (MG).
Financial Performance Overview
In Q1 of 2025, product sales of IDEFIRIX reached 65.7 million SEK, marking an increase from 47.4 million SEK in Q1 2024. The overall revenue for the quarter was 66.3 million SEK. The expansion of sites adopting IDEFIRIX, paired with increased repeated usage, contributed to this exceptional performance. Nonetheless, variations in European kidney allocation systems may lead to fluctuations in sales on a quarterly basis; Hansa expects a robust year-on-year product sales trajectory.
Progress on Pipeline Initiatives
During the first quarter of 2025, Hansa Biopharma finalized enrollment for the PAES study, which is crucial to supporting the full marketing authorization for IDEFIRIX in Europe. The outcomes from this study are anticipated to be revealed in 2026, fostering increased commercial use of imlifidase across participating centers.
After the favorable data from the Phase 2 trial, Hansa is thrilled to have this information accepted for oral presentation at a medical conference later this year, validating imlifidase’s ability to meet the significant needs within GBS treatment.
Moreover, the collaboration with Genethon on the GNT-018-IDES Phase 2 trial for patients with Crigler-Najjar syndrome is ongoing, progressing through patient enrollment efficiently.
Significantly, the pivotal Phase 3 trial, 20-HMedIdeS-17 (ConfIdeS), is poised to yield data results in late 2025, aiming to position imlifidase as a potential desensitization therapy for highly sensitized kidney transplant candidates.
Financial Summary of Q1 2025
Hansa Biopharma's financial summary presents the following highlights for Q1 2025:
- Total Revenue: 66.3 million SEK
- Product Sales: 65.7 million SEK
- SG&A Expenses: (76.0 million SEK)
- R&D Expenses: (64.3 million SEK)
- Loss from Operations: (93.4 million SEK)
- Loss for The Period: (37.1 million SEK)
- Cash and Short-Term Investments: 250.2 million SEK
As Hansa Biopharma moves forward, the company remains committed to achieving operational excellence and addressing the needs of patients through innovative therapies.
Upcoming Conference Call
Hansa Biopharma will hold a telephone conference to discuss these results on a specified date, hosted by Peter Nicklin, CFO Evan Ballantyne, and other key executives. This event will be inclusive of a comprehensive review of the interim financial results and a detailed update on the business and pipeline.
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
Stephanie Kenney, VP Global Corporate Affairs
About Hansa Biopharma
Hansa Biopharma is a pioneering biopharmaceutical company committed to developing groundbreaking treatments for patients facing rare immunological disorders. The company employs its unique IgG-cleaving enzyme technology platform to tackle pressing medical challenges in autoimmune diseases, gene therapy, and transplantation. Hansa’s portfolio includes its flagship product imlifidase and the innovative HNSA-5487. Hansa Biopharma operates out of Lund and has a significant presence across Europe and the U.S., making strides in the field of biopharmaceuticals.
Frequently Asked Questions
What were Hansa Biopharma's total revenues for Q1 2025?
The total revenues for Hansa Biopharma in Q1 2025 were 66.3 million SEK.
Who is the new CEO of Hansa Biopharma?
Renée Aguiar-Lucander has been appointed as the Chief Executive Officer effective immediately.
What is the primary product of Hansa Biopharma?
Hansa Biopharma's primary product is IDEFIRIX (imlifidase), an antibody-cleaving enzyme therapy.
When does Hansa expect outcomes from the PAES study?
Hansa Biopharma anticipates results from the PAES study to be available in the second half of 2026.
How many employees does Hansa Biopharma currently have?
As of now, Hansa Biopharma has 138 employees.
